Tanner Pharma Group to Distribute Novel Diagnostic Test in Latin America

TannerLAC UK Limited (“TannerLAC”), a part of Tanner Pharma Group, and Epimune Diagnostics (“Epimune”), a molecular diagnostic company, recently partnered to distribute the innovative diagnostic test, i.Mune TBNK®, in Latin America.

i.Mune TBNK® is an IVD product that quantifies CD3+, CD4+, CD8+ T-, B- and NK lymphocytes in fresh blood or a dried blood spot (DBS). Lymphocyte enumeration can be useful in follow-up and diagnostic evaluation of primary immunodeficiency, monitoring of HIV-positive patients, immune monitoring following immunosuppressive therapy for transplantation, autoimmunity and other immunological conditions, assessment of immune reconstitution post hematopoietic stem cell transplantation, early screening of gross quantitative anomalies in lymphocyte subsets in infections and malignancies and absolute quantification of circulating B cells for diagnosis of chronic lymphocytic leukemia (CLL) patients.

Epimune engaged TannerLAC to bring this revolutionary technology to immunodeficient patients in Latin American regions. TannerLAC recently received registration approval for the product in Peru, with registration pending in Colombia, Ecuador, Brazil and Mexico.

“We are very pleased with this milestone. This is the first of many registrations to come. Our team worked efficiently to expedite the registration process in Peru despite the many requirements to fulfill,” said Carolina Cortez, Executive Vice President of TannerLAC. “We are very excited about the opportunity to bring this innovative product to the country to support doctors with an additional tool for a successful diagnosis, and to help patients in remote communities who don’t have access to this type of test.”

To learn more about i.Mune TBNK® visit https://www.epimune-dx.com/english/products/i-mune-tbnk/.

About Tanner Pharma Group

For over 18 years, Tanner Pharma Group has partnered with companies to provide turn-key solutions to increase access to medicines and other medical technology around the world. By partnering with Tanner Pharma Group, companies are able to focus on their primary markets while ensuring that patients and clinicians in international markets can receive their products through a strictly controlled channel. Tanner Pharma Group is headquartered in the United States with offices in the United Kingdom, Switzerland, Ireland and Brazil. Tanner Pharma Group has a global reach and provides international commercialization and patient access through licensing, managed access programs, global access programs and clinical trial services. For more information, please visit www.tannerpharma.com.

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.